TARS · Healthcare · $3.4B
$77.37-1.58%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“XDEMVY 매출은 1억7,400만 달러로 전 분기 1억6,200만 달러에서 약 7% 늘었고, 최근 4개 분기 동안 1억1,900만→1억5,20”
In the company's words · 2026 2분기 earnings call